Class: Vitamin B Complex
VA Class: VT102
CAS Number: 59-30-3
Introduction
Water-soluble, B complex vitamin.a
Uses for Folic Acid
Anemia
Treatment of megaloblastic anemias due to folic acid deficiency as may be seen in tropical or nontropical sprue, nutritional anemias, and in anemias of pregnancy, infancy, and childhood.a
Dietary Requirements
Adequate intake of folate needed to prevent megaloblastic changes in the bone marrow and other rapidly dividing cells.140
Adequate intake of folate can be accomplished through consumption of foodstuffs, including folate-fortified foodstuffs, use of dietary supplements, or both.140
Prevention of Neural Tube Defects
Prophylactic therapy before and during pregnancy to reduce the risk of fetal neural tube defects, including spina bifida, anencephaly, and encephalocele.101 103 104 105 106 109 111 116 118 119 120 121 123 130 132 134 140 148
Cardiovascular Risk Reduction
No important benefit or harm of folic acid supplementation on the risk of cardiovascular disease, coronary heart disease, stroke, or all-cause mortality in patients with vascular disease.147
Folic Acid Dosage and Administration
Administration
Usually administered orally.a b May be administered by IM, sub-Q, or IV injection when oral administration is not feasible or when malabsorption is suspected.b However, most individuals with malabsorption are able to absorb oral folic acid.a
Dosage
Dosage of sodium folate injection is expressed in terms of folic acid.b
The Recommended Dietary Allowance (RDA) is expressed in terms of dietary folate equivalents/day.140 Dietary food folate equivalents (DFE) are calculated as follows: 1 mcg of dietary folate equivalent = 1 mcg of food folate = 0.5 mcg of folic acid taken in the fasting state = 0.6 mcg of folic acid taken with food.140
Pediatric Patients
Anemia
Oral or Parenteral
Up to 1 mg folic acid daily; some patients may require larger doses.a b
Usual maintenance dosage: 0.1 mg daily for infants, 0.3 mg daily for children <4 years of age, 0.4 mg daily for children ≥4 years of age.a b
Higher maintenance dosages may be required in patients with hemolytic anemia, chronic infections, and those receiving anticonvulsants.a b
Dietary Requirements
Oral
The Adequate Intake (AI) of folate for healthy infants <6 months of age is 65 mcg daily and for those 6–12 months of age is 80 mcg daily.140
The RDA for healthy children 1–3, 4–8, 9–13, or 14–18 years of age is 0.15, 0.2, 0.3, or 0.4 mg of DFE daily, respectively.140
Adults
Anemia
Oral or Parenteral
Up to 1 mg folic acid daily; some patients may require larger doses.a b
Usual maintenance dosage: 0.4 mg daily.a b
Usual maintenance dosage for pregnant and lactating women: 0.8 mg daily.a b
Higher maintenance dosages may be required in alcoholics, patients with hemolytic anemia, chronic infections, and patients receiving anticonvulsants.a b
Dietary Requirements
Oral
RDA for healthy adults: 0.4 mg DFE daily.140
RDA for lactating women: 0.5 mg DFE daily.140 Folate intake exceeding this RDA may be needed by mothers nursing more than one infant.140
Prevention of Neural Tube Defects
Oral
National Academy of Sciences: 0.4 mg of folic acid daily through fortified foods and/or supplements in addition to food folate consumed from a varied diet recommended for women of childbearing potential.140
The US Preventive Services Task Force: 0.4–0.8 mg of folic acid daily from supplements; initiate 1 month before conception and continue during the first 2–3 months of pregnancy.148
For women with a history of prior pregnancy complicated by neural tube defects: 4 mg folic acid daily initiated 1 month before and continued for 3 months after conception.c Such women should maintain the lower level of folic acid intake (i.e., 0.4 mg daily) during other periods of continued childbearing potential.c
RDA for pregnant women: 0.6 mg DFE daily.140 Folate intake exceeding this RDA may be needed by women who are pregnant with more than one fetus.140
Cautions for Folic Acid
Contraindications
-
Known intolerance.a
Warnings/Precautions
Warnings
Pernicious Anemia/Undiagnosed Anemia
Not indicated for pernicious anemia and other megaloblastic anemias due to vitamin B12 deficiency.a b Do not use in patients with undiagnosed anemia since folic acid may obscure the diagnosis of pernicious anemia by alleviating hematologic manifestations while allowing neurologic complications to progress.a b
Sensitivity Reactions
Allergic reactions (erythema, rash, itching, general malaise, bronchospastic respiratory difficulty, anaphylaxis) reported rarely.a
Specific Populations
Pregnancy
Category A.a
Lactation
Distributed into milk.a
Common Adverse Effects
Relatively nontoxic.a
Interactions for Folic Acid
Administration of phenytoin, primidone, barbiturates, methotrexate, nitrofurantoin, alcohol, or pyrimethamine may result in folate deficiency.a
Phenytoin
Possible increase in seizure frequency.a
Chloramphenicol
Possible delayed response to folic acidc
Folic Acid Pharmacokinetics
Absorption
Bioavailability
Well absorbed from the GI tract.a Synthetic folic acid is almost 100% bioavailable following oral administration in fasting individuals; folate in food is about 50% bioavailable.140
Food
Synthetic folic acid is 85–100% bioavailable following oral administration with a meal.140
Distribution
Extent
Distributed into all body tissues including the CNS; stored mainly in the liver.a
Elimination
Metabolism
Metabolized in the liver.a
Elimination Route
Up to 90% of a dose in urine; small amounts in feces.a
Stability
Storage
Oral
Tablets
15–30°C.a
Parenteral
Injection
15–30°C.b
Compatibility
For information on systemic interactions resulting from concomitant use, see Interactions.
Parenteral
Solution CompatibilityHID
Compatible |
---|
Amino acids 4.25%, dextrose 25% |
Dextrose 20% in water |
Incompatible |
Dextrose 40 or 50% in water |
Variable |
Fat emulsion 10%, IV |
Drug Compatibility
Compatible |
---|
Famotidine |
Actions
-
Folic acid is prepared synthetically.a 140 Naturally occurring conjugates of folic acid (food folate; pteroylpolyglutamates) are present in a wide variety of foods, particularly liver, kidneys, yeast, leafy green vegetables, other vegetables, citrus fruits and juice, and legumes.140
-
An exogenous source of folate is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis.a
-
Folic acid is not metabolically active as such, but is the precursor of tetrahydrofolic acid which is involved as a cofactor for 1-carbon transfer reactions in the biosynthesis of purines and thymidylates of nucleic acids.a
-
Folate supplementation before and during pregnancy associated with a reduction in risk for fetal neural tube defects.140
Advice to Patients
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a b
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.a b
-
Importance of informing patients of other important precautionary information.a b (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Bulk |
Powder* |
|||
Oral |
Tablets |
0.4 mg* |
Folic Acid Tablets |
|
0.8 mg* |
Folic Acid Tablets |
|||
1 mg* |
Folic Acid Tablets |
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
Injection |
equivalent to folic acid 5 mg/mL |
Folic Acid Injection |
AHFS DI Essentials. © Copyright 2017, Selected Revisions January 1, 2010. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
References
100. National Research Council Food and Nutrition Board Subcommittee on the Tenth Edition of the RDAs. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press; 1989:150-8.
101. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep. 1992; 41(RR-14):1-7.
102. Centers for Disease Control and Prevention. Use of folic acid for prevention of spina bifida and other neural tube defects—1983-1991. MMWR Morb Mortal Wkly Rep. 1991; 40:513-6. [PubMed 2072886]
103. Committee on Genetics. Folic acid for the prevention of neural tube defects. Pediatrics. 1993; 92:493-4. [PubMed 8361816]
104. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the medical research council vitamin study. Lancet. 1991; 338:131-7. [PubMed 1677062]
105. Anon. Folic acid and neural tube defects. Lancet. 1991; 338:153-4. [PubMed 1677069]
106. Laurence KM. Folic acid to prevent neural tube defects. Lancet. 1991; 338:379. [PubMed 1677712]
107. Taguchi H. Folic acid to prevent neural tube defects. Lancet. 1991; 338:506. [PubMed 1678458]
108. Reynolds EH. Folic acid to prevent neural tube defects. Lancet. 1991; 338:505-6. [PubMed 1678457]
109. Jick H, Jick SS, Milunsky A et al. Vitamins to prevent neural tube defects. Lancet. 1991; 338:639. [PubMed 1679181]
110. Super M, Summers EM, Meylan B. Preventing neural tube defects. Lancet. 1991; 338:775-6.
111. Grant A, Chalmers I. Vitamins to prevent neural tube defects. Lancet. 1991; 338:894.
112. Lucock MD, Wild J, Hartley R et al. Vitamins to prevent neural tube defects. Lancet. 1991; 338:894-5.
113. Davies DP. Vitamins to prevent neural tube defects. Lancet. 1991; 338:895. [PubMed 1681258]
114. Smithells RW, Sheppard S, Schorah CJ. Folic acid to prevent neural tube defects. Lancet. 1991; 338:379-8. [PubMed 1677712]
115. Scott JM, Kirke P, O’Broin et al. Folic acid to prevent neural tube defects. Lancet. 1991; 338:505. [PubMed 1678457]
116. Jukes TH. Vitamins to prevent neural tube defects. Lancet. 1991; 338:640. [PubMed 1679182]
117. Leeming RJ, Blair JA, Brown SE. Vitamins to prevent neural tube defects. Lancet. 1991; 338:895. [PubMed 1681258]
118. American Academy of Pediatrics. Daily folic acid use reduces birth defects. Elk Grove Village, IL; 1993 Sep 8. Press release.
119. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA. 1993; 269:1257-61. [PubMed 8437302]
120. Oakley GP Jr. Folic acid—preventable spina bifida and anencephaly. JAMA. 1993; 269:1292-3. [PubMed 8437310]
121. Sutcliffe M, Schorah CJ, Perry A et al. Prevention of neural tube defects. Lancet. 1991; 338:379. [PubMed 1677712]
122. Centers for Disease Control and Prevention. Possible adverse effects of folic acid consumption; meeting. Prescription Pharm. 1993; 58:40149.
123. Elwood M. Folic acid prevents neural tube defects. Med J Aust. 1991; 155:579-81. [PubMed 1943950]
124. Holmes LB. Prevention of neural tube defects. J Pediatr. 1992; 120:918-9. [PubMed 1593351]
125. Glanville NT, Cook HW. Folic acid and prevention of neural tube defects. CMAJ. 1992; 146:39. [PubMed 1728351]
126. Milunsky A, Jick H, Jick SS et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA. 1989; 262:2847-52. [PubMed 2478730]
127. Mills JL, Rhoads GG, Simpson JL et al. Vitamins during pregnancy and neural tube defects. JAMA. 1990; 263:2747-8. [PubMed 2332916]
128. Shapiro S, Mitchell AA, Werler MM. Vitamins during pregnancy and neural tube defects. JAMA. 1990; 263:2748.
129. Milunsky A, Jick H, Jick SS et al. Vitamins during pregnancy and neural tube defects. JAMA. 1990; 263:2748-9.
130. Vergel RG, Sanchez LR, Heredero BL et al. Primary prevention of neural tube defects with folic acid supplementation: cuban experience. Prenatal Diagn. 1990; 10:149-52.
131. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in western Australia. Med J Aust. 1989; 150:613-9. [PubMed 2725375]
132. Griffin JP. Vitamins and neural tube defects. BMJ. 1988; 296:430. [PubMed 3125934]
133. World Health Organization. Folic acid and spina bifida. WHO Drug Info. 1993; 7:106-8.
134. Wald NJ, Bower C. Folic acid, pernicious anaemia, and prevention of neural tube defects. Lancet. 1994; 343:307. [PubMed 7905138]
135. Beresford SAA. Annotation: how do we get enough folic acid to prevent some neural tube defects? Am J Public Health. 1994; 84:348-50.
136. US Food and Drug Administration. [FDA proposes that folic acid be added to flour, breads, and other grains.] Rockville, MD; 1993 Oct 8. Press release.
137. Foulke J (US Food and Drug Administration). Folic acid to fortify U.S. food products to prevent birth defects. Rockville, MD; 1996 Feb 29. Press Release No. P96-3.
138. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption; folic acid (folacin). 21 CFR Part 172. Final rule. [Docket No. 91N-100F]. Fed Regist. 1996; 61:8797-8807.
139. Tucker KL, Mahnken B, Wilson PWF et al. Folic acid fortification of the food supply: potential benefits and risks for the elderly population. JAMA. 1996; 276:1879-85. [PubMed 8968013]
140. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes of the Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press; 1998. (Prepublication copy uncorrected proofs.)
141. Ubbink JB. Should all elderly people receive folate supplements? Drugs Aging. 1998; 13:415-20.
142. McCully KS. Homocysteine, folate, vitamin B6, and cardiovascular disease. JAMA. 1998; 279:392-3. [PubMed 9459475]
143. Rimm EB, Willett WC, Hu FB et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998; 279:359-64. [PubMed 9459468]
144. Malinow MR, Duell PB, Hess DL et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998; 338:1009-15. [PubMed 9535664]
145. Homocysteine Lowering Trialists’ Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 1998; 316:894-8. [PubMed 9569395]
146. The Homocysteine Studies Collaborative. Homocysteine and risk of ischemic heart disease and stroke; a meta-analysis. JAMA. 2002; 288:2015-22. [PubMed 12387654]
147. Bazzano LA, Reynolds K, Holder KN et al. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006; 296: 2720-26. [PubMed 17164458]
148. US Preventive Services Task Force. Folic acid for the prevention of neural tube defects: US Preventive Services Task Force recommendation statement. Ann Inter Med. 2009; 150:626-31.
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:746-8.
a. Danbury Pharmacal. Folic acid tablets, USP prescribing information. Danbury, CT: 1998 Jul.
b. Lederle Laboratories. Folvite folic acid tablets-parenteral solution prescribing inforation (dated Jan 1988). In: Physicians’ desk reference. 43rd edition. Montevale, NJ: Medical Economics Company Inc; 1989:1120
c. AHFS drug information 2003. McEvoy GK, ed. Folic Acid. Bethesda, MD: American Society of Health-System Pharmacists; 2003: page 3500-2.
More about folic acid
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 2 Reviews – Add your own review/rating
- Drug class: vitamins
Consumer resources
Professional resources
Other brands: FaLessa